scispace - formally typeset
Open AccessJournal ArticleDOI

Search-and-replace genome editing without double-strand breaks or donor DNA

Reads0
Chats0
TLDR
A new DNA-editing technique called prime editing offers improved versatility and efficiency with reduced byproducts compared with existing techniques, and shows potential for correcting disease-associated mutations.
Abstract
Most genetic variants that contribute to disease1 are challenging to correct efficiently and without excess byproducts2-5. Here we describe prime editing, a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a catalytically impaired Cas9 endonuclease fused to an engineered reverse transcriptase, programmed with a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit. We performed more than 175 edits in human cells, including targeted insertions, deletions, and all 12 types of point mutation, without requiring double-strand breaks or donor DNA templates. We used prime editing in human cells to correct, efficiently and with few byproducts, the primary genetic causes of sickle cell disease (requiring a transversion in HBB) and Tay-Sachs disease (requiring a deletion in HEXA); to install a protective transversion in PRNP; and to insert various tags and epitopes precisely into target loci. Four human cell lines and primary post-mitotic mouse cortical neurons support prime editing with varying efficiencies. Prime editing shows higher or similar efficiency and fewer byproducts than homology-directed repair, has complementary strengths and weaknesses compared to base editing, and induces much lower off-target editing than Cas9 nuclease at known Cas9 off-target sites. Prime editing substantially expands the scope and capabilities of genome editing, and in principle could correct up to 89% of known genetic variants associated with human diseases.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

TL;DR: This work analyzes key considerations when choosing genome editing agents and identifies opportunities for future improvements and applications in basic research and therapeutics.

Therapeutic genome editing: prospects and challenges

TL;DR: Current progress toward developing programmable nuclease–based therapies as well as future prospects and challenges are discussed.
Journal ArticleDOI

The promise and challenge of therapeutic genome editing

Jennifer A. Doudna
- 12 Feb 2020 - 
TL;DR: The scientific, technical and ethical aspects of using CRISPR technology for therapeutic applications in humans are discussed, highlighting both opportunities and challenges of this technology to treat, cure and prevent genetic disease.
Journal ArticleDOI

Applications of CRISPR–Cas in agriculture and plant biotechnology

TL;DR: The most important applications of CRISPR-Cas in increasing plant yield, quality, disease resistance and herbicide resistance, breeding and accelerated domestication, and prospective applications of this game-changing technology are discussed.
References
More filters
Journal ArticleDOI

Flap Endonuclease 1: A Central Component of DNA Metabolism

TL;DR: FEN1 is a genome stabilization factor that prevents flaps from equilibrating into structures that lead to duplications and deletions and interacts with other nucleases and helicases that allow it to act efficiently on structured flaps.
Journal ArticleDOI

Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area.

TL;DR: It is demonstrated that dopaminergic neurons of the substantia nigra do not allow for long-term expression from adenoviral vectors, and strikingly, these neurons appeared to specifically attenuate transgene expression by deleting the adenviral genome.
Journal ArticleDOI

The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans-splicing reaction

TL;DR: The naturally split α subunit of the DNA polymerase III (DnaE) intein from Nostoc punctiforme PCC73102 (Npu) is studied using purified proteins and an apparent first‐order rate constant of 1.1 ± 0.2 s−1 is determined, which represents the highest rate reported for the protein trans‐splicing reaction so far.
Related Papers (5)